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Background: Vascular dementia (VD) is a series of clinical and
neurophysiological manifestations caused by cerebrovascular disease. As
the human lifespan increases, the number of people affected by
age‐related dementia is growing at an alarming pace, but no proved
therapeutic methods can stop it from getting worse.
Objective: To investigate the neurorestorative effects of injecting
olfactory ensheathing cells (OECs), Schwann cells (SCs), and olfactory
receptor neurons (ORNs) into olfactory sub‐mucosa in VD patients.
Methods: A pilot study of double‐blind randomized controlled cell
therapies was conducted in VD patients (n = 5). Cells were injected into
the patients’ olfactory sub‐mucosa. Two patients received OEC
treatment, one received SC treatment, one ORN treatment, and one OEC
combined with ORN. Mental state and cognitive function were observed
before treatment and 1, 3, 6, and 12 months after treatment. magnetic
resonance imaging (MRI) or computed tomography (CT) was performed
before treatment and 12 months after treatment.
Results: The directional function score on the Mini‐Mental Status
Examination (MMSE) in the patient who received SC treatment had
increased slightly 1 and 3 months after treatment. The scores for
orientation, attention, delayed verbal recall, and repetition increased in
the ORN group patient 1 month after treatment. The orientation and
repetition scores of the ORN group patient continued to increase 3 months
after treatment. The scores for attention, delayed verbal recall, and phase 3
command decreased in the OEC and the OEC + ORN group patients after
treatment assessment Scores on the Montreal Cognitive Assessment
(MoCA) and Clinical Dementia Rating (CDR) scale also improved in the
ORN group patient. Clinical and MRI or CT examinations did not find any
side effects from the cell therapy or transplanting procedure.
Conclusion: All of the cell transplantations were found to be safe. ORN
was shown to be a promising therapy for VD patients. Phase II clinical
trials of ORN, SC, and OEC therapy are required to verify their effects on
VD symptoms, especially ORNs.

© The authors 2021. This article
is published with open access at
http://jnr.tsinghuajournals.com
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1

Introduction

Vascular dementia (VD) is a common disease
with clinical and neuropathological manifesta‐
tions caused by a series of cerebrovascular
events. It is the second leading cause of
dementia in the elderly after Alzheimer’s disease
(AD) [1]. Vascular pathology significantly affects
cognitive function, leading to dementia and
cognitive impairment. The clinical variability
and unpredictability of disease progression in
VD pose significant challenges to contemporary
medicine. In dementia, hypoperfusion and
vascular dysfunctions produce amyloid toxicity
and other causes of memory impairment. These
accelerate the progression of AD and other
memory disorders. Thus far, treatments for
dementia have not produced significantly
positive results [2]. VD patients often exhibit
memory loss, attention and task execution
disorders, such as slowed thinking; disorienta‐
tion; a decline in planning, reasoning, judgment,
and problem solving ability; and reduced ability
of daily living (ADL) [3]. The vascular impair‐
ment of cognition classification consensus study
(VICCCS) classified VD into eight subtypes:
vascular mild cognitive impairment, multi‐
infarct dementia (cortical VD), subcortical
ischemic VD, strategic‐infarct dementia, hypoper‐
fusion dementia, hemorrhagic dementia, dementia
caused by specific arteriopathies, and mixed AD
and VD [4]. The differing types of VD lead to
different symptoms but, so far, the detail
pathogenesis of VD is unclear. It is well known
that arteriosclerosis, cerebral (micro) infarction,
and amyloidosis are the main causes of vascular
dementia and cerebral small vessel disease is the
most crucial risk factor in VD. Other risk factors
include age, genetic factors, history of stroke,
hypertension, cardiac disorders, atherosclerosis,
diabetes, and metabolic syndrome. Unfortun‐

ately, the mechanisms underlying VD are not yet
fully understood [5]. Chronic hypoperfusion,
hypoxia, oxidative stress, inflammatory factors,
microvascular dysfunction, and blood–brain
barrier (BBB) degradation are believed to be
involved [6].
At present, the treatment options for VD are
limited. Treatment strategies are based on risk
factor control and cognitive function improve‐
ment. Acetylcholinesterase inhibitors such as
donepezil, rivastigmine, and galantamine have
been approved for mild to moderate AD, but
they do not improve the overall function of VD
patients. They can also neither prevent the
occurrence nor slow down or reverse the
progress of VD [7]. In recent years, cell therapy
for neurodegenerative diseases has attracted
extensive attention. There is evidence that cell
transplantation can improve the symptoms of
cerebral infarction and VD, making it a potential
treatment for VD [8]. Olfactory ensheathing cells
(OECs) are a kind of glial cells that share the
functions of both Schwann cells (SCs) and
oligodendrocytes [9]. Schwann cells contribute
to peripheral nerve regeneration. Olfactory
receptor neurons (ORNs) can adapt to different
environments to become functional neurons [10].
We conducted this pilot clinical study to
determine whether OECs, ORNs, and SCs are
viable treatments for patients with VD.

2
2.1

Materials and methods
Study design

This was a pilot, two‐center, randomized,
double‐blind, controlled clinical study. The
objective was to investigate the effects and the
safety of OEC, ORN, and SC injections into the
olfactory sub‐mucosa of patients with VD. The
study was conducted in accordance with the
tenets of the Declaration of Helsinki and
Journal of Neurorestoratology
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approved by the ethics committees of the
participating hospitals. Informed consents were
obtained from patients and their relatives.
2.2

Participants

The study recruited 5 participants（4 males and 1
female）aged 48 to 79 years old (mean age = 65.8
years), diagnosed with VD. According to the
Diagnostic and Statistical Manual of Mental
Disorders (DSM‐IV), and the International
Classification of Diseases (ICD‐10) [11, 12], the
diagnostic criteria for VD (formerly known as
multiple infarct dementia) are as follows: (1)
dementia that meets the diagnostic criteria of
the DSM‐IV‐R; (2) diagnosis of cerebrovascular
disease with support from clinical and imaging
findings; (3) dementia is closely related to
cerebrovascular disease, occurs within 3 months
of stroke, lasts for more than 6 months, may be
suddenly aggravated, fluctuate, or gradually
progress; (4) test results support a diagnosis of
vascular dementia according to the following: (a)
heterogeneity of cognitive impairment (plaque
damage), (b) the personality remains relatively
intact, (c) the course of disease fluctuates and
there is a history of multiple strokes, (d) gait
disorders, pseudobulbar paralysis.
The exclusion criteria for patients with VD
were as follows: (1) disturbance of conscious‐
ness; (2) dementia caused by other diseases of
the nervous system such as Alzheimerʹs disease,
Parkinson’s disease, Lewy body dementia, or
Pick’s disease; (3) dementia caused by systemic
diseases; (4) mental illness such as depression
[13]. We also excluded people diagnosed with
mixed dementia and those diagnosed without
the use of imaging techniques or brain scans to
determine the subtype of dementia.
The inclusion criteria for patients with VD
were as follows: (1) Basic condition was patients
aged 45–80 years, who had capacity to give
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informed consent, and were willing and able to
participate in the follow‐up study. (2) For
possible VD patients, based on (a) imaging
evidence of cognitive impairment and cere‐
brovascular disease, (b) a clear temporal
correlation between vascular events (such as
stroke) and cognitive impairment, (c) a clear
correlation between the severity and distribu‐
tion of cognitive impairment and pathological
changes due to diffuse subcortical cerebrovas‐
cular disease (such as cerebral autosomal
dominant arteriopathy with subcortical infarcts
and leukoencephalopathy); and had (d) no
evidence of progressive cognitive impairment
due to non‐vascular neurodegenerative disease
before or after stroke. (3) For VD patients: (a)
cognitive function decreased in at least two
areas compared to a baseline level to a severity
that affects activities of daily life, (b) a diagnosis
of dementia based on tests of cognitive function
that evaluate executive function/attention,
memory, language, and visuospatial function, (c)
patient was in stable, non‐acute stage (stable
condition for at least two weeks) with good
vision and hearing and the ability to complete
neuropsychological tests, (d) current treatment
with cholinesterase inhibitors (donepezil,
rivastigmine, or galantamine), excitatory amino
acid receptor antagonists (memantine), anti‐
depressants (such as sertraline, citalopram,
paroxetine, or venlafaxine) was not an exclusion
criterion but the above drugs could be taken
only after 4 weeks in which the VD was stable,
(e) with a Clinical Dementia Rating (CDR) Score
between 0.5 and 2.
Participants were withdrawn from the study
if they: (1) formally withdraw consent; (2)
experienced complications unrelated to the
study that might affect the results; (3) used
unconventional drugs such as neurotrophic
factors; (4) had adverse drug reactions unrelated
to the study; (5) had other severe medical
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conditions; (6) failed to complete the follow‐up;
(7) died from unrelated causes. Data for
dropouts were not included in the final result
analyses.
2.3

Cell preparation and procedure

ORN and SC preparation was the same as that
in our previous published paper [14]. ORN pre‐
paration and identification met the professional
quality control standards of Chinese Association
of Neurorestoratology (CANR; Preparatory) [15].
Olfactory receptor neurons were derived from
the olfactory mucosa of an aborted fetus (an
approval and signed donation consent form was
first obtained) and cultured in Dulbecco’s
modified Eagle’s medium (DMEM/F12; Gibco)
with the neurotrophic factors. Cells were
allowed to proliferate and differentiate
according to patented methods (China Patent:
ZL201510 935540.3 2019.09.24) until the volume
was appropriate for clinical transplantation.
Olfactory receptor neurons were visualized by
immunostaining Tuj‐1 (over 85%). All cells used
in this study were cultured and prepared by the
Third Medical Center of General Hospital of

Fig. 1

PLA and Beijing Hongtianji Neuroscience
Academy, China.
The cells were injected into the olfactory
sub‐mucosa of patients. Figure 1 shows the cell
injection procedure. The procedure was the
same as that used in our previous published
paper [14]. Each participant was injected with
0.3 mL medium on each side of the septum with
5 × 106 OECs, or 5 × 106 SCs, or 5 × 106 ORNs, or
2.5 × 106 OECs + 2.5 × 106 ORNs.
2.4

Assessment of outcomes

Physicians conducted assessments at the two
participating hospitals in this pilot study. All
assessing physicians received training in the
standardization of assessments. Participants
were assessed before treatment for baseline
scores and then at intervals of 1, 3, 6, and 12
months post‐treatment. The Mini‐Mental Status
Examination (MMSE), Montreal Cognitive
Assessment (MoCA), and CDR were used as
assessment methods. magnetic resonance
imaging (MRI) or computed tomography (CT)
brain scans were performed before treatment (or
at baseline) and 12 months after treatment.

Diagram of cell injection and migration. After the cells were injected into the olfactory sub‐mucosa, they migrated into the olfactory

bulb and then to the lesion area. Reproduced from Ref. [14] with permission from the authors, © the authors.
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Sample size, randomization, and blinding

As a clinical observation study, this pilot
recruited one or two participants for each kind
of cell therapy to test the safety and effects of
each. All participants were randomly assigned
by a technician. The technician performed the
cell culture procedure but had no further
involvement.

Participants

and

all

study

personnel were blinded to the cell treatment
assigned to each patient.

dropped a little at that time but was still higher
than before treatment. In the patient who
received OEC + ORN treatment, scores for
attention, delayed verbal recall, and three‐stage
command dropped after treatment.
The scores of the patient who received SC
treatment remained stable after the treatment.
The scores in 2 patients with OEC treatment still
got worsen after treatment. Even one patient’s
visuospatial/executive and orientation increased
1 month or 3 months after treatment, but the
score dropped in later follow‐up. Besides his

3

Results

attention and abstraction scores continually
decreased, the scores of visuospatial/executive,

This pilot study was conducted between 6th

naming, abstraction, and orientation in the ORN

November, 2017 and 20th June, 2019. There were

group patient increased at each time point after

5

treatment.

participants.

One

patient

received

SC

The

attention,

language,

and

treatment, one received ORN treatment, one

abstraction scores of the OEC + ORN patient

received OEC + ORN treatment, and two

continually worsened at each time point after

received OEC treatment.

treatment.

Functional status was assessed using MMSE
(Table 1), MoCA (Table 2), and CDR (Table 3).
In the patient who received the SC treatment,
orientation scores had increased a little 1 and 3
months after treatment, but the naming score
had decreased 6 months after treatment. All
scores of the 2 patients who received OEC
treatment continued to decrease at each time
point after treatment. One of the 2 patients
showed increased orientation and immediate
recall scores 1 month after treatment, but these
scores also dropped after that. And this patient’s

CDR scores remained stable in the SC group
patient after treatment. The scores for memory,
judgment and problem solving, community
affairs, home and hobbies, and personal care
worsened after treatment in 1 OEC group
patient. The CDR assessment scores of the other
OEC patient remained stable after the treatment.
The CDR scores of the ORN patient improved
after treatment. The CDR scores of the OEC +
ORN group patient remained stable after
treatment.

three‐stage command and writing continually

The MRI or CT brain scans taken before and

decreased. In the patient who received ORN

after intervention did not show significant

treatment, the scores for orientation, attention,

differences in all patients. There were no

delayed verbal recall, and repetition increased 1

neoplasms in the scans taken 1 year after

month after treatment. The scores for orientation,

treatment. There were no adverse events related

and repetition further increased 3 months after

to either the cell therapy or the transplanting

treatment. The score for delayed verbal recall

procedure in any of the patients.
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Table 1

Functional scores on MMSE.
Baseline

1 month after
treatment

Total
Orientation
Immediate recall
Attention
Delayed verbal recall
Naming
Repetition
3‐stage command
Writing
Total
Orientation

6
2
2
0
0
2
0
0
0
15
5

8
3
3
0
0
2
0
0
0
15
6

8
3
3
0
0
2
0
0
0
12
6

6
3
3
0
0
0
0
0
0
10
5

6
3
3
0
0
0
0
0
0
10
5

Immediate recall

1

2

0

0

0

Assessment score
SC group
(n = 1)

OEC group
(n = 2)

Patient A

Patient B

ORN group
(n = 1)

OEC + ORN
group
(n = 1)

3 months after 6 months after
treatment
treatment

1 year after
treatment

Attention

1

1

1

1

1

Delayed verbal recall

0

0

0

0

0

Naming

2

2

2

2

2

Repetition

1

1

1

1

1

3‐stage command

3

1

1

0

0

Writing

1

1

0

0

0

Total

17

18

13

13

12

Orientation

7

5

4

4

4

Immediate recall

2

3

2

2

2

Attention

1

1

1

1

1

Delayed verbal recall

1

2

0

0

0

Naming

2

2

2

2

2

Repetition

0

1

1

1

0

3‐stage command

3

3

2

2

2

Writing

0

0

0

0

0

Total
Orientation
Immediate recall
Attention
Delayed verbal recall
Naming
Repetition
3‐stage command
Writing
Total
Orientation

15
4
3
0
0
2
0
3
1
27
9

23
5
3
5
2
2
0
3
1
24
9

24
6
3
5
1
2
1
3
1
24
9

24
6
3
5
1
2
1
3
1
23
9

24
6
3
5
1
2
1
3
1
23
9

Immediate recall

3

3

3

3

3

Attention

5

3

3

3

3

Delayed verbal recall

2

2

2

1

1

Naming

2

2

2

2

2

Repetition

1

1

1

1

1

3‐stage command
Writing

3
1

2
1

2
1

2
1

2
1

SC, Schwann cell; OEC, olfactory ensheathing cell; ORN, olfactory receptor neuron.
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Functional scores on MoCA.
Baseline

1 month after
treatment

Total

0

0

0

0

0

Visuospatial/executive

0

0

0

0

0

Naming

0

0

0

0

0

Attention

0

0

0

0

0

Language

0

0

0

0

0

Abstraction

0

0

0

0

0

Delayed recall

0

0

0

0

0

Assessment score
SC group
(n=1)

OEC group
(n = 2)

Patient A

Patient B

ORN group
(n = 1)

OEC + ORN
group
(n = 1)

3 months after 6 months after
treatment
treatment

1 year after
treatment

Orientation

0

0

0

0

0

Total

10

11

7

6

6

Visuospatial/executive

0

1

2

1

1

Naming

3

3

3

3

3

Attention

3

2

0

0

0

Language

0

0

0

0

0

Abstraction

2

2

0

0

0

Delayed recall

0

0

0

0

0

Orientation

2

3

2

2

2

Total

13

11

8

6

5

Visuospatial/executive

0

0

0

0

0

Naming

3

3

3

3

3

Attention

1

2

1

0

0

Language

1

1

0

0

0

Abstraction

1

2

1

1

0

Delayed recall

1

0

0

0

0

Orientation

6

3

3

2

2

Total

5

8

10

11

11

Visuospatial/executive

1

2

2

3

3

Naming

2

3

3

3

3

Attention

0

0

0

0

0

Language

0

0

0

0

0

Abstraction

0

0

2

2

2

Delayed recall

0

0

0

0

0

Orientation

2

3

3

3

3

Total

23

20

19

19

19

Visuospatial/executive

3

3

3

3

3

Naming

3

3

3

3

3

Attention

7

7

6

6

6

Language

2

1

1

1

1

Abstraction

2

0

0

0

0

Delayed recall

0

0

0

0

0

Orientation

6

6

6

6

6

SC, Schwann cell; OEC, olfactory ensheathing cell; ORN, olfactory receptor neuron.
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Table 3

Functional scores on CDR scale.
Baseline

1 month after
treatment

3 months after
treatment

6 months after
treatment

1 year after
treatment

CDR

3

3

3

3

3

Memory

3

2

2

3

3

Orientation

2

2

2

2

2

Judgment and
problem solving

3

3

3

3

3

Community affairs

3

3

3

3

3

Home and hobbies

3

3

3

3

3

Personal care

3

3

3

3

3

CDR

1

3

3

3

3

Memory

2

3

3

3

3

Orientation

3

3

3

3

3

Judgment and
problem solving
Community affairs

1

3

3

3

3

1

3

3

3

3

Home and hobbies

1

3

3

3

3

Personal care

0

3

3

3

3

CDR

2

2

2

2

2

Memory

2

2

2

2

2

Orientation

1

1

1

1

1

Judgment and
problem solving

2

2

3

3

3

Community affairs

2

2

2

2

2

Home and hobbies

3

3

3

3

3

Personal care

2

2

2

2

2

CDR

2

2

1

1

1

Memory

2

2

2

2

2

Orientation

2

0.5

0.5

0.5

0.5

Judgment and
problem solving

2

1

1

1

1

Community affairs

2

1

1

1

1

Home and hobbies

2

2

2

2

2

Personal care

0

2

1

1

0

CDR

1

1

1

1

1

Memory

1

1

1

1

1

Orientation

1

1

1

1

1

Judgment and
problem solving

1

1

1

1

1

Community affairs

0.5

1

1

1

1

Home and hobbies

1

1

1

1

1

Personal care

0

0

0

0

0

Assessment score
SC group
(n = 1)

OEC group
(n = 2)

Patient A

Patient B

ORN group
(n = 1)

OEC + ORN
group
(n = 1)

SC, Schwann cell; OEC, olfactory ensheathing cell; ORN, olfactory receptor neuron.
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Discussion

On all three evaluation methods in this pilot
study, ORN treatment showed potential
neurorestorative effects for patients with VD.
Holbrook et al. [16] found that human olfactory
tissue can regenerate and restore itself
throughout one’s life. The olfactory nervous
system may be the only nervous tissue that can
regenerate throughout life. Lu et al. [10] found
that ORNs show characteristics of photoreceptor
cells in vitro. In animal experiments, olfactory
ecto‐mesenchymal stem cells (containing, or
differentiated into, ORNs) adopted a neuronal
phenotype at injury sites [17]. Another study
showed that immediate or delayed trans‐
planting of a vein conduit filled with olfactory
ecto‐mesenchymal stem cells improved loco‐
motion and exogenesis [18]. These studies
demonstrate that ORNs are highly adaptable to
different environments. They may migrate to
lesion areas, establish synaptic connections with
the host neurons and integrate functions after
transplantation. This may be why ORNs
restored the neurological functions of our VD
patient in this pilot study.
Since neuron loss is the main pathological
change in VD, transplanting ORNs may replace
lost host neurons, reset synaptic connections
with living host neurons, and restore neuronal
circuits. However, it seems that the dosage of
ORNs must be sufficiently high as a lower dose
of ORNs combined with OECs in this study did
not show neurorestorative effects. ORNs can
also secrete neurotrophins, which may also help
to restore host neuronal dysfunctions.
OECs have been shown to improve
neurological functions and patients’ quality of
life in the majority of clinical studies of spinal
cord injury (SCI) [19, 20] and other neurological
diseases or damage [21], especially chronic
ischemic stroke [14]. We were therefore

145

surprised that OECs or OECs combined with
ORNs did not show positive effects on VD in
this pilot study. It may be that the neurotrophins
secreted by OECs may be insufficient to improve
the dysfunctions or lost functions in VD.
SCs showed some neurorestorative effects in
our MMSE assessment. This requires further
experimental exploration and confirmation. In
previous clinical studies, SCs have demon‐
strated both positive [22] and negative [23, 24]
effects on SCI, and positive effects on
Parkinson’s disease [25]
There were no side effects related to cell
therapy and transplanting procedure. Some
kinds of cells did not affect VD patients in this
pilot study.
There has been increasing interest in recent
years in the use of clinical cell therapy for the
treatment of many neurological diseases and
neurological damage, including dementia [26].
Research has shown such therapy to have
positive neurorestorative effects on most
neurological conditions. As this was a pilot
study involving a small number of patients, our
findings are tentative. Nevertheless, the
promising effects of ORN treatment on our
patient were encouraging and warrant further
research in a phase II clinical trial.

5

Conclusion

ORN, OEC, and SC transplantation were found
to be safe. ORN treatment was found to be a
promising therapy for VD patients. A phase II
clinical trial of these cell therapies, especially
ORNs, is needed to verify our findings.
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